Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

EMERYVILLE, Calif., March 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor. The FOCUS trial is designed to support the registrational filing with the European Medicines Agency (EMA) in patients with relapsed and refractory myeloma.  

The FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) trial modification includes two key enhancements to the study: changing the primary end point to overall survival (OS) from progression-free survival (PFS) and correspondingly increasing patient enrollment to 300 from 84.  These modifications are supported by overall survival data from the Phase 2b 003-A1 study evaluating single-agent carfilzomib in patients with relapsed and refractory multiple myeloma announced at the American Society of Hematology (ASH) meeting in December 2010.  The company expects to review these data with the EMA and is moving forward with plans to do so.

"Given the encouraging carfilzomib data reported to date, including the 003-A1 survival data, Onyx decided to make this change to demonstrate a potential mortality benefit for carfilzomib," said Ted Love, M.D., executive vice president, research and development and technical operations at Onyx.  "We plan to upsize the trial at the currently active sites by leveraging the momentum we are seeing in enrollment as well as by adding additional sites, as appropriate."

Focus Trial Design

As modified, the Phase 3 FOCUS study will be a randomized 300-patient trial evaluating carfilzomib versus best supportive care of low dose steroids plus cytoxan (optional), in patients with relapsed and refractory multip
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... ... recently hosted their 2015 bi-annual Pain Management Medical Advisory Board meeting in Palm ... Biosciences’ executive Research and Development team to discuss new clinical practice and research ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... cheaper molecular diagnostic tests are key drivers of the global molecular diagnostics market. ... medicine and the introduction of new companion diagnostic tests will increase demand for ...
(Date:7/6/2015)... , July 6, 2015 Navitas, a leading Regulatory Service ... America hub in Bogota, Colombia . Navitas, ... the many benefits provided by Colombia , the third ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... location, allows US based clients to communicate with Navitas regulatory professionals in ...
(Date:7/3/2015)... ... July 03, 2015 , ... DryLet, ... as animal waste reduction, bioremediation, wastewater treatment, aquaculture and grease, fat and ... that it will be showcasing, ManureMagic™, its industry-leading product for animal waste ...
Breaking Biology Technology:Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2
... BioSciences, Inc. (Nasdaq: SGMO ) announced ... protein (ZFP) technology. New research published in the ... Dow AgroSciences and Sangamo demonstrated the successful application ... maize plants with multiple, commercially important traits. The ...
... Software Download - 4TB4Free , ... Austin, Texas (PRWEB) ... storage software for accessing, storing and distributing content, today announced the ... processors, customers can run virtual CAStor nodes in a single, physical ...
... significant financial obligation and improves balance sheetROCKVILLE, Md., April ... a leader in the development of novel vaccines, today ... with holders of $17 million of the total $22 ... carried a coupon rate of 4.75% payable semi-annually and ...
Cached Biology Technology:Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 2Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 3Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 4Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2Novavax Announces Early Retirement of $17 Million of Convertible Debt 2Novavax Announces Early Retirement of $17 Million of Convertible Debt 3
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... . . . With a network ... seismic activity, traffic, bacteria on beaches, water levels and ... to expand. Sensorpedia, developed three years ago by Oak ... first responders, individuals and communities with online sensor data ...
... ARBOR, Mich. Why do some diseases affect only ... of Michigan have found neural tissue contains imbalanced levels ... a debilitating childhood movement disorder. Known as ... movements or abnormal postures. It,s caused by a mutation ...
... 1. Discover the latest in Earth and Space Sciences ... findings in the Earth and space sciences in Foz do ... the meeting, which takes place from 8 to 12 August, ... 2010 Haiti and Chile earthquakes, extreme weather events in the ...
Cached Biology News:Story tips from the US Department of Energy's Oak Ridge National Laboratory -- June 2010 2Neural tissue contains imbalanced levels of proteins, U-M study finds 22010 Meeting of the Americas, Brazil: News media registration open 22010 Meeting of the Americas, Brazil: News media registration open 32010 Meeting of the Americas, Brazil: News media registration open 4
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SPDP-Trinitrophenol (TNP) Bovine Serum Albumin...
Biology Products: